ADAR1 Partners Discloses 9.9% Stake in Cellectar Biosciences

TL;DR

**ADAR1 Partners just revealed a 9.9% stake in Cellectar Biosciences, signaling a bullish institutional bet.**

AI Summary

ADAR1 Partners, LP, a Texas-based investment firm, reported on January 31, 2024, that it holds 9.9% of Cellectar Biosciences, Inc.'s common stock, with the event triggering this filing occurring on January 23, 2024. This significant stake, while not a controlling interest, indicates ADAR1's strong belief in Cellectar's future, potentially signaling a positive outlook for current and prospective investors in the pharmaceutical company.

Why It Matters

This filing reveals a notable institutional investor's confidence in Cellectar Biosciences, which could influence market perception and stock price.

Risk Assessment

Risk Level: low — This filing indicates a significant investment by an institutional holder, generally seen as a positive signal rather than a risk.

Analyst Insight

Investors should note this significant institutional stake as a potential vote of confidence and consider researching Cellectar Biosciences' fundamentals and pipeline developments.

Key Numbers

• 9.9% — Percentage of Class Owned (Represents ADAR1 Partners, LP's ownership stake in Cellectar Biosciences, Inc.)
• January 23, 2024 — Date of Event (The specific date that triggered the requirement for ADAR1 Partners, LP to file this Schedule 13G.)
• January 31, 2024 — Filing Date (The date this SC 13G filing was submitted to the SEC.)
• $0.00001 — Par Value per Share (The nominal value of each share of Cellectar Biosciences, Inc. Common Stock.)

Key Players & Entities

• ADAR1 Partners, LP (company) — reporting person and institutional investor
• Cellectar Biosciences, Inc. (company) — subject company whose stock is being reported
• ADAR1 CAPITAL MANAGEMENT GP, LLC (company) — group member of reporting entity
• ADAR1 CAPITAL MANAGEMENT, LLC (company) — group member of reporting entity
• Daniel Schneeberger (person) — group member of reporting entity
• 03 Life Sciences (company) — organization name associated with Cellectar Biosciences

Forward-Looking Statements

• Cellectar Biosciences' stock price may see a short-term positive reaction due to increased institutional interest. (Cellectar Biosciences, Inc.) — medium confidence, target: 2024-02-29
• ADAR1 Partners, LP may increase its stake in Cellectar Biosciences if the company's pipeline progresses positively. (ADAR1 Partners, LP) — low confidence, target: 2024-12-31

FAQ

Key Financial Figures

• $0.00001 — me of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securiti

Filing Documents

• tm244656d1_sc13g.htm (SC 13G) — 102KB
• 0001104659-24-008548.txt ( ) — 104KB

(a)

Item 1(a) Name of issuer: Cellectar Biosciences, Inc.

(b)

Item 1(b) Address of issuer’s principal executive offices: 100 Campus Drive, Florham Park, New Jersey 07932

(a)

Item 2(a) Name of person filing: This Schedule is being filed on behalf of each of the following persons (each, a “ Reporting Person ” and collectively, the “ Reporting Persons ”) i) ADAR1 Partners, LP (“ ADAR1 Fund ”); ii) ADAR1 Capital Management, LLC (“ ADAR1 Capital Management ”); iii) ADAR1 Capital Management GP, LLC (“ ADAR1 General Partner ”); and iv) Daniel Schneeberger (“ Mr. Schneeberger ”) This Schedule relates to shares of common stock of the Issuer, par value $0.00001 per share (“ Shares ”), directly held by ADAR1 Fund. ADAR1 Capital Management acts as an investment adviser to, and manages investment and trading accounts of, ADAR1 Fund. ADAR1 General Partner acts as the general partner of ADAR1 Fund. ADAR1 Capital Management and ADAR1 General Partner may be deemed to indirectly beneficially own securities held by ADAR1 Fund. Mr. Schneeberger is the Manager of ADAR1 Capital Management and ADAR1 General Partner. Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Fund. Each Reporting Person declares that neither the filing of this Schedule nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act) with any other person as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any syndicate or group with respect to the Issuer or any securities of the Issuer.

(b)

Item 2(b) Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.

(c)

Item 2(c) Citizenship: i) ADAR1 Fund is a Delaware limited partnership; ii) ADAR1 Capital Management is a Texas limited liability company; iii) ADAR1 General Partner is a Texas limited liability company; and iv) Mr. Schneeberger is a citizen of Switzerland. 6

(d)

Item 2(d) Title of Class of Securities: Common Stock, par value $0.00001 per share

(e)

Item 2(e) CUSIP No.: 15117F807 Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________. 7 Item 4. (a) Amount Beneficially Owned: As of January 23, 2024, each of the Reporting Persons could have been deemed to be the beneficial owner of 1,824,063 Shares. Since January 23, 2024, the Reporting Persons have sold some Shares, and as of the date hereof, each of the Reporting Persons may be deemed to be the beneficial owner of 1,197,193 Shares. (b) Percent of Class: As of January 23, 2024, each of the Reporting Persons could have been deemed to be the beneficial owner of approximately 6.21% of the Shares outstanding , based on 29,360,000 Shares outstanding as of January 23, 2024. Since January 23, 2024, the Reporting

View Full Filing

View this SC 13G filing on SEC EDGAR